Marché mondial des infections par le virus de l’hépatite Delta (VHD) – Tendances et prévisions de l’industrie jusqu’en 2031

Personnalisez votre rapport Personnalisez votre rapport Acheter maintenantAcheter maintenant Exemple de rapport gratuitExemple de rapport gratuit
Maison Pharmaceutical Global Hepatitis Delta Virus Hdv Infection Market
Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché mondial des infections par le virus de l’hépatite Delta (VHD) – Tendances et prévisions de l’industrie jusqu’en 2031

  • Pharmaceutical
  • Publish Reports
  • Nov 2024
  • Global
  • 350 Pages
  • Nombre de tableaux : 703
  • Nombre de figures : 61
Buy Now Acheter maintenant

Global Hepatitis Delta Virus Hdv Infection Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
 2024 –2031
Diagram Taille du marché (année de référence)
 USD 47.34 Million
Diagram Taille du marché (année de prévision)
 USD 68.24 Million
Diagram TCAC
 %
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>
Demande de déverrouillage

>Marché mondial de l'infection par le virus de l'hépatite Delta (VHD), par type (hépatite D aiguë et hépatite D chronique), traitement (chirurgie ( transplantation hépatique ) et médicaments), type de médicament (de marque et générique), voie d'administration (orale et parentérale), groupe d'âge (adultes, gériatrique et pédiatrique), sexe (femme et homme), transmission (aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques, et autres), utilisateur final (hôpitaux, cliniques spécialisées, établissements de soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire, et autres), canal de distribution (appel d'offres direct, ventes au détail, et autres) - Tendances et prévisions de l'industrie jusqu'en 2031

Marché de l'infection par le virus de l'hépatite Delta (VHD)

Analyse et perspectives du marché de l'infection par le virus de l'hépatite Delta (VHD)

La prévalence croissante de l'hépatite, en particulier de l'hépatite B, influence considérablement le marché mondial de l'infection par le virus de l'hépatite Delta (VHD). L'hépatite D est une infection du foie causée par le virus de l'hépatite D (VHD), qui nécessite la présence du virus de l'hépatite B (VHB) pour se répliquer. À mesure que les infections par l'hépatite B augmentent à l'échelle mondiale, le nombre de personnes susceptibles d'être infectées par le VHD augmente également. Ce nombre croissant de personnes infectées par le VHB crée une population cible plus large pour le VHD, ce qui stimule la demande de solutions diagnostiques et thérapeutiques spécifiques au VHD.

Marché de l'infection par le virus de l'hépatite Delta (VHD)Marché de l'infection par le virus de l'hépatite Delta (VHD)

Data Bridge Market Research analyse que le marché mondial de l'infection par le virus de l'hépatite Delta (HDV) devrait atteindre 68,24 millions USD d'ici 2031, contre 47,34 millions USD en 2023, avec un TCAC de 4,8 % au cours de la période de prévision de 2024 à 2031.

Rapport métrique

Détails

Période de prévision

2024 à 2031

Année de base

2023

Années historiques

2022 (personnalisable pour 2016-2021)

Unités quantitatives

Chiffre d'affaires en millions USD

Segments couverts

Type (hépatite D aiguë et hépatite D chronique), traitement (chirurgie (transplantation hépatique) et médicaments), type de médicament (de marque et générique), voie d'administration (orale et parentérale), groupe d'âge (adultes, gériatriques et pédiatriques), sexe (femme et homme), transmission (aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques, et autres), utilisateur final (hôpitaux, cliniques spécialisées, établissements de soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire, et autres), canal de distribution (appel d'offres direct, vente au détail, et autres)

Pays couverts

États-Unis, Canada, Mexique, Allemagne, France, Royaume-Uni, Italie, Espagne, Pays-Bas, Suisse, Russie, Belgique, Turquie, Danemark, Suède, Pologne, Norvège, Finlande, Reste de l'Europe, Chine, Japon, Inde, Corée du Sud, Australie, Thaïlande, Malaisie, Indonésie, Singapour, Philippines, Nouvelle-Zélande, Vietnam, Taïwan, Reste de l'Asie-Pacifique, Brésil, Argentine, Reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Bahreïn, Koweït, Oman, Qatar et Reste du Moyen-Orient et de l'Afrique

Acteurs du marché couverts

GILEAD SCIENCES, INC., GENENTECH, INC., ALNYLAM PHARMACEUTICALS, INC., ASSEMBLY BIOSCIENCES, INC., EIGER BIOPHARMACEUTICALS, GLOBEIMMUNE INC., HUAHUI HEALTH LTD., JOHNSON & JOHNSON SERVICES, INC., PHARMAESSENTIA CORPORATION, REPLICOR, VIR BIOTECHNOLOGY, INC.

Market Definition

Hepatitis Delta (HDV) infection is a rare but severe form of viral hepatitis that occurs when the Hepatitis Delta Virus (HDV) infects a liver already infected with Hepatitis B Virus (HBV). HDV is a defective virus that requires HBV to replicate and produce new viral particles, and it is characterized by its ability to rapidly cause liver disease, including acute hepatitis, liver failure, and even death. The coinfection of HBV and HDV leads to a more severe and rapid progression of liver disease compared to HBV infection alone, and it is often associated with higher levels of liver inflammation and fibrosis.

Global Hepatitis Delta Virus (HDV) Infection Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:      

Drivers

  • Growing Prevalence of Hepatitis

The growing prevalence of hepatitis, particularly hepatitis B, is significantly influencing the global Hepatitis Delta Virus (HDV) infection market. Hepatitis D is a liver infection caused by the Hepatitis D Virus (HDV), which requires the presence of the Hepatitis B Virus (HBV) to replicate. As hepatitis B infections increase globally, the number of individuals susceptible to HDV infection also rises. This growing pool of HBV-infected individuals creates a larger target population for HDV, thus driving demand for diagnostic and therapeutic solutions specific to HDV.

  • Increase in Healthcare Expenditure

The increase in healthcare expenditure has a significant impact on the growth of the global Hepatitis Delta Virus (HDV) infection market by facilitating more substantial investment in diagnostic technologies and treatment options. As healthcare budgets expand, governments and healthcare organizations are able to allocate more resources towards advanced diagnostic tools for HDV. This investment leads to the development and deployment of more sensitive and accurate testing methods, which enhances early detection rates and drives up demand for diagnostic services. The improved availability of high-quality diagnostic tests contributes directly to market growth by increasing the overall testing and screening activities. Moreover, higher healthcare expenditure often translates into better access to and affordability of treatment options for HDV. As funding increases, there is greater potential for the development and distribution of innovative antiviral therapies and other medical interventions. This expanded access to effective treatments not only improves patient outcomes but also stimulates market growth by creating a more extensive patient base seeking treatment options. Enhanced therapeutic options can lead to better disease management and higher rates of treatment adherence, further boosting demand within the HDV infection market.

Marché de l'infection par le virus de l'hépatite Delta (VHD)

Opportunity

  • Rising Innovative Drug Development

Pipeline therapies like JNJ-73763989 and Peginterferon Lambda are creating new opportunities for pharmaceutical companies to address the substantial unmet need for effective treatments in this space. JNJ-73763989 is a ground-breaking therapy designed to inhibit the replication of HDV by targeting essential components of the viral life cycle, offering a more precise and potentially effective approach compared to existing treatments. On the other hand, Peginterferon Lambda, a novel form of interferon therapy, is being evaluated for its ability to provide antiviral effects while minimizing the side effects traditionally associated with interferon-based treatments. Its targeted mechanism of action has the potential to improve patient outcomes by offering a more tolerable therapy option.

Restraint/Challenge

  • Limited Awareness of Hepatitis Delta Virus (HDV)

Limited awareness of Hepatitis Delta Virus (HDV) infection is a significant restraint for the global HDV infection market. Many healthcare providers and patients are not aware of the risks and consequences of HDV infection, leading to delayed diagnosis and treatment. This lack of awareness results in patients being diagnosed with liver disease at an advanced stage, making treatment more challenging and increasing the risk of complications and mortality.

  • Side Effects of Current Treatments

L'interféron alpha pégylé est une option thérapeutique clé pour la prise en charge du VHD en raison de sa capacité à induire une réponse virale soutenue. Cependant, son utilisation est entravée par une série d'effets secondaires invalidants qui peuvent avoir un impact significatif sur l'observance du traitement par le patient.

Les effets secondaires courants de l'interféron alpha pégylé comprennent des symptômes pseudo-grippaux tels que fièvre, frissons et douleurs musculaires, ainsi que des problèmes plus graves tels que fatigue, troubles gastro-intestinaux et effets psychologiques tels que dépression et anxiété. Ces effets secondaires peuvent être pénibles pour les patients, entraînant souvent une diminution de la qualité de vie et des difficultés à maintenir un traitement régulier. La gravité de ces effets indésirables peut décourager les patients de terminer le traitement prescrit, ce qui entraîne des résultats thérapeutiques sous-optimaux et une progression potentielle de la maladie.

Développements récents

  • En septembre 2024, Gilead Sciences, Inc. et Genesis Therapeutics ont formé une collaboration stratégique pour découvrir et développer de nouvelles thérapies à l'aide de technologies avancées de découverte de médicaments basées sur l'IA. Ce partenariat vise à accélérer la création de traitements innovants, à améliorer le portefeuille de Gilead et à renforcer sa position dans le secteur biopharmaceutique concurrentiel
  • En mars 2024, Gilead Sciences Inc. a finalisé l'acquisition de CymaBay Therapeutics, ce qui lui a permis d'accéder à des thérapies innovantes pour les maladies du foie et les maladies rares. Cette acquisition élargit le portefeuille de recherche de Gilead et renforce son pipeline, améliorant ainsi sa capacité à répondre à des besoins médicaux non satisfaits. L'acquisition de CymaBay fournit à Gilead de nouveaux candidats médicaments prometteurs et une expertise dans le domaine des maladies du foie et des maladies rares, renforçant ainsi ses capacités de recherche et élargissant son offre thérapeutique
  • En mars 2024, Gilead Sciences, Inc. et Merus ont annoncé une collaboration visant à découvrir de nouveaux anticorps engageant les cellules T trispécifiques, dans le but d'améliorer l' immunothérapie contre le cancer. Ce partenariat associe l'expertise de Gilead à la technologie innovante de Merus pour développer des traitements avancés contre le cancer
  • En mars 2024, Alnylam Pharmaceuticals a lancé le Family Health History Road Trip pour promouvoir les discussions sur l'amylose héréditaire ATTR (hATTR). La généalogiste Bernice Bennett a parcouru le pays pour souligner l'importance des antécédents médicaux familiaux pour un diagnostic plus précoce

Portée du marché mondial de l'infection par le virus de l'hépatite Delta (VHD)

Le marché mondial de l'infection par le virus de l'hépatite Delta (VHD) est segmenté en neuf segments notables en fonction du type, du traitement, du type de médicament, de la voie d'administration, de la tranche d'âge, du sexe, de la transmission, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et les différences entre vos marchés cibles.

Taper

  • Hépatite D aiguë
  •  Hépatite D chronique

Sur la base du type, le marché est segmenté en hépatite D aiguë et hépatite D chronique.

Traitement

  • Chirurgie (transplantation du foie)
  • Médicament

En fonction du traitement, le marché est segmenté en chirurgie (transplantation du foie) et en médicaments.

Type de médicament

  • De marque
  • Générique

En fonction du type de médicament, le marché est segmenté en médicaments de marque et génériques.

Voie d'administration

  • Oral
  • Parentérale

Sur la base de la voie d’administration, le marché est segmenté en voie orale et parentérale.

Tranche d'âge

  • Adultes
  •  Gériatrie
  •  Pédiatrique

Sur la base de la tranche d’âge, le marché est segmenté en adultes, gériatriques et pédiatriques.

Genre

  • Femelle
  •  Mâle

Sur la base du sexe, le marché est segmenté en femmes et en hommes.

Transmission

  • Aiguilles contaminées
  •  Exposition au sang infecté
  •  Transfusion de produits sanguins et plasmatiques
  •  Autres

Sur la base de la transmission, le marché est segmenté en aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques et autres.

Utilisateur final

  • Hôpitaux
  •  Cliniques spécialisées
  •  Cadre de soins à domicile
  •  Instituts de recherche et centres universitaires
  •  Centres de chirurgie ambulatoire
  •  Autres

Sur la base de l'utilisateur final, le marché est segmenté en hôpitaux, cliniques spécialisées, soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire et autres.

Canal de distribution

  • Appel d'offres direct
  •  Ventes au détail
  • Autres

Sur la base du canal de distribution, le marché est segmenté en appels d'offres directs, ventes au détail et autres.

Analyse/perspectives régionales du marché mondial des infections par le virus de l'hépatite Delta (VHD)

Le marché mondial de l’infection par le virus de l’hépatite Delta (HDV) est segmenté en neuf segments notables en fonction du type, du traitement, de la voie d’administration, de la forme posologique, du groupe d’âge, du sexe, de la transmission, de l’utilisateur final et du canal de distribution.

Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada, le Mexique, l'Allemagne, la France, le Royaume-Uni, l'Italie, l'Espagne, les Pays-Bas, la Suisse, la Russie, la Belgique, la Turquie, le Danemark, la Suède, la Pologne, la Norvège, la Finlande, le reste de l'Europe, la Chine, le Japon, l'Inde, la Corée du Sud, l'Australie, la Thaïlande, la Malaisie, l'Indonésie, Singapour, les Philippines, la Nouvelle-Zélande, le Vietnam, Taïwan, le reste de l'Asie-Pacifique, le Brésil, l'Argentine, le reste de l'Amérique du Sud, l'Afrique du Sud, l'Arabie saoudite, les Émirats arabes unis, l'Égypte, Bahreïn, le Koweït, Oman, le Qatar et le reste du Moyen-Orient et de l'Afrique.

L'Europe devrait dominer le marché mondial de l'infection par l'hépatite Delta (HDV), en raison de la forte prévalence du HDV dans des pays comme la Russie, l'Ukraine et les pays d'Europe de l'Est, où il constitue un problème de santé publique majeur et stimule la demande de solutions de diagnostic et de traitement. L'Allemagne devrait dominer la région Europe en raison des progrès des technologies de diagnostic. La Chine devrait dominer la région Asie-Pacifique en raison des initiatives de recherche et développement en cours. Les États-Unis devraient dominer la région Amérique du Nord en raison de l'augmentation des dépenses de santé.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité de grandes entreprises de services et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des acteurs locaux et nationaux et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Marché de l'infection par le virus de l'hépatite Delta (VHD)

Analyse du paysage concurrentiel et des parts de marché mondiales liées à l'infection par le virus de l'hépatite Delta (VHD)

Le paysage concurrentiel du marché mondial de l'infection par l'hépatite Delta (HDV) fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.

Certains des principaux acteurs du marché opérant sur le marché sont Gilead Sciences, Inc., Genentech, Inc., Eiger BioPharmaceuticals, Johnson & Johnson Services, Inc., Assembly Biosciences, Inc., PharmaEssentia Corporation, Vir Biotechnology, Inc., Huahui Health Ltd., Replicor, GlobeImmune Inc. et Alnylam Pharmaceuticals, Inc. entre autres.

SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Sample Image Cliquez sur l'image pour l'agrandir
  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTER FIVE FORCES

4.3 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET

4.4 DISTRIBUTION OF PRODUCTS BY PHASE

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING PREVALENCE OF HEPATITIS

6.1.2 INCREASE IN HEALTHCARE EXPENDITURE

6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES

6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES

6.2 RESTRAINTS

6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV)

6.2.2 HIGH COST OF TREATMENT

6.3 OPPORTUNITIES

6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT

6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES

6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS

6.4 CHALLENGES

6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS

6.4.2 SLOW REGULATORY APPROVALS

7 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE

7.1 OVERVIEW

7.2 ACUTE HEPATITIS D

7.3 CHRONIC HEPATITIS D

8 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT

8.1 OVERVIEW

8.2 SURGERY (LIVER TRANSPLANT)

8.3 MEDICATION

8.3.1 APPROVED THERAPIES

8.3.1.1 PEGYLATED INTERFERON ALPHA

8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE)

8.3.2 EMERGING THERAPIES

9 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM

9.1 OVERVIEW

9.2 TABLET

9.3 CAPSULE

9.4 INJECTABLE

10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE

10.1 OVERVIEW

10.2 BRANDED

10.3 GENERIC

11 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 CAPSULE

11.2.3 OTHERS

11.3 PARENTERAL

12 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER

12.1 OVERVIEW

12.2 FEMALE

12.3 MALE

13 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP

13.1 OVERVIEW

13.2 ADULTS

13.3 GERIATRIC

13.4 PEDIATRIC

14 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION

14.1 OVERVIEW

14.2 CONTAMINATED NEEDLES

14.3 EXPOSURE TO INFECTED BLOOD

14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION

14.5 OTHERS

15 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECIALTY CENTERS

15.4 HOME CARE SETTING

15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS

15.6 AMBULATORY SURGICAL CENTERS

15.7 OTHERS

16 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

16.3.1 HOSPITAL PHARMACY

16.3.2 RETAIL PHARMACY

16.3.3 ONLINE PHARMACY

16.4 OTHERS

17 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION

17.1 OVERVIEW

17.2 EUROPE

17.2.1 GERMANY

17.2.2 FRANCE

17.2.3 U.K

17.2.4 ITALY

17.2.5 SPAIN

17.2.6 NETHERLANDS

17.2.7 SWITZERLAND

17.2.8 RUSSIA

17.2.9 BELGIUM

17.2.10 TURKEY

17.2.11 DENMARK

17.2.12 SWEDEN

17.2.13 POLAND

17.2.14 NORWAY

17.2.15 FINLAND

17.2.16 REST OF EUROPE

17.3 MIDDLE EAST AND AFRICA

17.4 NORTH AMERICA

17.4.1 U.S.

17.4.2 CANADA

17.4.3 MEXICO

17.5 ASIA PACIFIC

17.6 SOUTH AMERICA

18 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: GLOBAL

18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

18.3 COMPANY SHARE ANALYSIS: EUROPE

18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 GILEAD SCIENCES, INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PIPELINE PRODUCT

20.1.5 RECENT DEVELOPMENTS

20.2 GENENTECH, INC.

20.2.1 COMPANY SNAPSHOT

20.2.2 PRODUCT PORTFOLIO

20.2.3 RECENT DEVELOPMENT

20.3 ALNYLAM PHARMACEUTICALS, INC.

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 PIPELINE PRODUCT

20.3.4 RECENT DEVELOPMENTS

20.4 ASSEMBLY BIOSCIENCES, INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 PIPELINE PRODUCT

20.4.4 RECENT DEVELOPMENTS

20.5 EIGER BIOPHARMACEUTICALS

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 PIPELINE PRODUCT

20.5.6 RECENT DEVELOPMENT

20.6 GLOBEIMMUNE INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 PIPELINE PRODUCT

20.6.3 RECENT DEVELOPMENT

20.7 HUAHUI HEALTH LTD.

20.7.1 COMPANY SNAPSHOT

20.7.2 PIPELINE PRODUCT

20.7.3 RECENT DEVELOPMENT

20.8 JOHNSON & JOHNSON SERVICES, INC.

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PIPELINE PRODUCT

20.8.4 RECENT DEVELOPMENT

20.9 PHARMAESSENTIA CORPORATION

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PIPELINE PRODUCT

20.9.4 RECENT DEVELOPMENT

20.1 REPLICOR

20.10.1 COMPANY SNAPSHOT

20.10.2 PIPELINE PRODUCT

20.10.3 RECENT DEVELOPMENTS

20.11 VIR BIOTECHNOLOGY, INC.

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANALAYSIS

20.11.3 PRODUCT PIPELINE

20.11.4 RECENT DEVELOPMENTS

21 QUESTIONNAIRE

22 RELATED REPORTS

Liste des tableaux

TABLE 1 EMERGING NOVEL THERAPIES FOR HDV

TABLE 2 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 3 GLOBAL ACUTE HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL CHRONIC HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 6 GLOBAL SURGERY (LIVER TRANSPLANT) IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL TABLET IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL CAPSULE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL INJECTABLE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL BRANDED IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL GENERIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL PARENTERAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 22 GLOBAL FEMALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 GLOBAL MALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 24 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 25 GLOBAL ADULTS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 26 GLOBAL GERIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 27 GLOBAL PEDIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 28 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 29 GLOBAL CONTAMINATED NEEDLES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 30 GLOBAL EXPOSURE TO INFECTED BLOOD IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 31 GLOBAL BLOOD AND PLASMA PRODUCT TRANSFUSION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 32 GLOBAL OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 33 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 34 GLOBAL HOSPITALS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 35 GLOBAL SPECIALTY CLINICS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 36 GLOBAL HOME CARE SETTING IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 37 GLOBAL RESEARCH INSTITUTES AND ACADEMIC CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 38 GLOBAL AMBULATORY SURGICAL CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 39 GLOBAL OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 40 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 41 GLOBAL DIRECT TENDER IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 42 GLOBAL RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 43 GLOBAL RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 44 GLOBAL OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 45 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 46 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 47 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 48 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 49 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 50 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 51 EUROPE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 53 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 54 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 55 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 56 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 57 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 58 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 59 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 60 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 61 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 62 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 64 GERMANY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 GERMANY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 67 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 68 GERMANY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 70 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 71 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 72 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 73 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 74 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 75 GERMANY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 78 FRANCE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 79 FRANCE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 80 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 81 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 82 FRANCE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 84 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 85 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 86 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 87 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 88 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 89 FRANCE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 92 U.K. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 U.K. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 94 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 95 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 96 U.K. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 97 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 98 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 99 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 100 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 101 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 102 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 103 U.K. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 106 ITALY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 107 ITALY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 108 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 109 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 110 ITALY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 112 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 113 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 114 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 115 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 116 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 117 ITALY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 119 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 120 SPAIN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 121 SPAIN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 122 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 124 SPAIN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 126 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 127 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 128 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 129 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 130 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 131 SPAIN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 132 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 134 NETHERLANDS MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 NETHERLANDS APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 136 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 138 NETHERLANDS ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 139 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 140 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 141 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 142 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 143 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 144 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 145 NETHERLANDS RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 146 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 147 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 148 SWITZERLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 SWITZERLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 150 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 151 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 152 SWITZERLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 154 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 155 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 156 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 157 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 158 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 159 SWITZERLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 160 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 161 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 162 RUSSIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 163 RUSSIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 164 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 165 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 166 RUSSIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 168 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 169 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 170 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 171 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 172 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 173 RUSSIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 174 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 175 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 176 BELGIUM MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 177 BELGIUM APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 178 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 180 BELGIUM ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 181 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 182 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 183 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 184 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 185 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 186 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 187 BELGIUM RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 188 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 189 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 190 TURKEY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 191 TURKEY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 193 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 194 TURKEY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 196 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 197 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 198 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 199 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 200 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 201 TURKEY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 202 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 203 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 204 DENMARK MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 DENMARK APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 207 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 208 DENMARK ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 209 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 210 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 211 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 212 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 213 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 214 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 215 DENMARK RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 216 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 218 SWEDEN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 SWEDEN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 220 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 221 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 222 SWEDEN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 223 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 224 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 225 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 226 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 227 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 228 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 229 SWEDEN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 230 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 231 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 232 POLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 POLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 234 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 235 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 236 POLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 238 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 239 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 240 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 241 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 242 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 243 POLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 246 NORWAY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 247 NORWAY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 248 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 249 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 250 NORWAY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 251 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 252 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 253 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 254 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 255 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 256 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 257 NORWAY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 258 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 259 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 260 FINLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 261 FINLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 262 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 263 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 264 FINLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 265 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 266 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 267 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 268 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 269 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 270 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 271 FINLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 272 REST OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 273 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 274 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 275 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 276 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 277 MIDDLE EAST AND AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 278 MIDDLE EAST AND AFRICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 279 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 280 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 281 MIDDLE EAST AND AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 282 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 283 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 284 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 285 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 286 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 287 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 288 MIDDLE EAST AND AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 289 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 290 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 291 SAUDI ARABIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 292 SAUDI ARABIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 293 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 294 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 295 SAUDI ARABIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 297 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 298 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 299 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 300 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 301 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 302 SAUDI ARABIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 303 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 304 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 305 SOUTH AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 SOUTH AFRICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 307 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 308 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 309 SOUTH AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 310 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 311 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 312 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 313 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 314 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 315 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 316 SOUTH AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 317 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 318 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 319 U.A.E MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 320 U.A.E APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 321 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 322 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 323 U.A.E ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 324 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 325 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 326 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 327 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 328 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 329 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 330 U.A.E RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 332 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 333 EGYPT MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 EGYPT APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 335 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 336 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 337 EGYPT ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 338 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 339 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 340 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 341 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 342 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 343 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 344 EGYPT RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 345 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 346 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 347 BAHRAIN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 348 BAHRAIN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 349 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 350 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 351 BAHRAIN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 352 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 353 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 354 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 355 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 356 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 357 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 358 BAHRAIN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 359 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 360 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 361 KUWAIT MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 362 KUWAIT APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 363 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 364 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 365 KUWAIT ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 366 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 367 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 368 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 369 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 370 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 371 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 372 KUWAIT RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 373 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 374 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 375 OMAN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 376 OMAN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 379 OMAN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 380 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 381 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 382 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 383 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 384 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 385 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 386 OMAN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 387 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 388 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 389 QATAR MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 390 QATAR APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 391 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 392 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 393 QATAR ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 394 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 395 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 396 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 397 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 398 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 399 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 400 QATAR RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 401 REST OF MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 402 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 403 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 404 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 405 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 406 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 407 NORTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 408 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 409 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 410 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 411 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 412 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 413 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 414 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 415 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 416 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 417 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 418 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 419 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 420 U.S. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 421 U.S. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 422 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 423 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 424 U.S. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 425 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 426 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 427 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 428 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 429 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 430 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 431 U.S. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 432 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 433 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 434 CANADA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 435 CANADA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 436 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 437 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 438 CANADA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 439 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 440 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 441 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 442 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 443 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 444 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 445 CANADA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 446 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 447 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 448 MEXICO MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 449 MEXICO APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 450 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 451 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 452 MEXICO ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 453 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 454 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 455 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 456 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 457 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 458 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 459 MEXICO RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 460 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 461 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 462 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 463 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 464 ASIA-PACIFIC MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 465 ASIA-PACIFIC APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 466 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 467 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 468 ASIA-PACIFIC ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 469 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 470 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 471 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 472 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 473 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 474 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 475 ASIA-PACIFIC RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 476 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 477 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 478 CHINA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 479 CHINA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 480 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 481 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 482 CHINA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 483 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 484 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 485 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 486 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 487 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 488 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 489 CHINA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 490 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 491 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 492 JAPAN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 493 JAPAN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 494 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 495 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 496 JAPAN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 497 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 498 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 499 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 500 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 501 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 502 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 503 JAPAN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 504 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 505 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 506 INDIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 507 INDIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 508 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 509 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 510 INDIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 511 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 512 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 513 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 514 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 515 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 516 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 517 INDIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 518 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 519 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 520 SOUTH KOREA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 521 SOUTH KOREA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 522 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 523 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 524 SOUTH KOREA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 525 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 526 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 527 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 528 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 529 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 530 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 531 SOUTH KOREA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 532 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 533 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 534 AUSTRALIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 535 AUSTRALIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 536 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 537 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 538 AUSTRALIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 539 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 540 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 541 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 542 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 543 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 544 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 545 AUSTRALIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 546 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 547 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 548 THAILAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 549 THAILAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 550 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 551 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 552 THAILAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 553 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 554 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 555 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 556 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 557 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 558 THAILAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 559 THAILAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 560 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 561 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 562 MALAYSIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 563 MALAYSIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 564 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 565 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 566 MALAYSIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 567 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 568 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 569 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 570 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 571 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 572 MALAYSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 573 MALAYSIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 574 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 575 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 576 INDONESIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 577 INDONESIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 578 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 579 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 580 INDONESIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 581 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 582 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 583 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 584 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 585 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 586 INDONESIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 587 INDONESIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 588 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 589 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 590 SINGAPORE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 591 SINGAPORE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 592 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 593 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 594 SINGAPORE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 595 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 596 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 597 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 598 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 599 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 600 SINGAPORE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 601 SINGAPORE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 602 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 603 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 604 PHILIPPINES MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 605 PHILIPPINES APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 606 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 607 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 608 PHILIPPINES ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 609 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 610 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 611 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 612 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 613 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 614 PHILIPPINES HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 615 PHILIPPINES RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 616 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 617 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 618 NEW ZEALAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 619 NEW ZEALAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 620 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 621 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 622 NEW ZEALAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 623 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 624 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 625 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 626 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 627 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 628 NEW ZEALAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 629 NEW ZEALAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 630 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 631 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 632 VIETNAM MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 633 VIETNAM APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 634 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 635 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 636 VIETNAM ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 637 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 638 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 639 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 640 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 641 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 642 VIETNAM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 643 VIETNAM RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 644 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 645 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 646 TAIWAN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 647 TAIWAN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 648 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 649 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 650 TAIWAN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 651 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 652 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 653 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 654 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 655 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 656 TAIWAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 657 TAIWAN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 658 REST OF ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 659 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 660 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 661 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 662 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 663 SOUTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 664 SOUTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 665 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 666 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 667 SOUTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 668 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 669 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 670 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 671 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 672 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 673 SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 674 SOUTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 675 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 676 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 677 BRAZIL MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 678 BRAZIL APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 679 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 680 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 681 BRAZIL ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 682 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 683 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 684 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 685 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 686 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 687 BRAZIL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 688 BRAZIL RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 689 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 690 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 691 ARGENTINA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 692 ARGENTINA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 693 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 694 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 695 ARGENTINA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 696 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 697 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 698 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 699 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)

TABLE 700 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 701 ARGENTINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 702 ARGENTINA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 703 REST OF SOUTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

Liste des figures

FIGURE 1 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION

FIGURE 2 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: END USER COVERAGE GRID

FIGURE 8 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION

FIGURE 11 TWO SEGMENTS COMPRISE THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE

FIGURE 12 GROWING PREVALENCE OF HEPATITIS IS DRIVING THE GROWTH OF THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET FROM 2024 TO 2031

FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN 2024 AND 2031

FIGURE 14 EUROPE IS EXPECTED TO DOMINATE THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 15 EUROPE IS THE FASTEST-GROWING REGION FOR GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET

FIGURE 17 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2023

FIGURE 18 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2024-2031 (USD THOUSAND)

FIGURE 19 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 20 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 21 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2023

FIGURE 22 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)

FIGURE 23 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)

FIGURE 24 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 25 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2023

FIGURE 26 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)

FIGURE 27 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, CAGR (2024-2031)

FIGURE 28 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 29 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2023

FIGURE 30 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 31 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 32 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 33 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 34 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 35 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 36 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 37 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER,2023

FIGURE 38 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, 2024-2031 (USD THOUSAND)

FIGURE 39 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 40 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, LIFELINE CURVE

FIGURE 41 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2023

FIGURE 42 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)

FIGURE 43 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, CAGR (2024-2031)

FIGURE 44 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 45 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2023

FIGURE 46 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2024-2031 (USD THOUSAND)

FIGURE 47 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, CAGR (2024-2031)

FIGURE 48 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, LIFELINE CURVE

FIGURE 49 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2023

FIGURE 50 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 51 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, CAGR (2024-2031)

FIGURE 52 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, LIFELINE CURVE

FIGURE 53 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 54 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 55 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 56 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 57 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SNAPSHOT (2023)

FIGURE 58 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

FIGURE 59 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

FIGURE 60 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

FIGURE 61 AISA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The market is segmented based on Global Hepatitis Delta Virus (HDV) Infection Market, By Type (Acute Hepatitis D and Chronic Hepatitis D), Treatment (Surgery (Liver Transplant) and Medication), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral), Age Group (Adults, Geriatric, and Pediatric), Gender (Female and Male), Transmission (Contaminated Needles, Exposure to Infected Blood, Blood and Plasma Product Transfusion, and Others), End User (Hospitals, Specialty Clinics, Home Care Setting, Research Institutes and Academic Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031 .
The Global Hepatitis Delta Virus Hdv Infection Market size was valued at USD 47.34 USD Million in 2023.
The Global Hepatitis Delta Virus Hdv Infection Market is projected to grow at a CAGR of 4.8% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Switzerland, Russia, Belgium, Turkey, Denmark, Sweden, Poland, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Singapore, Philippines, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Bahrain, Kuwait, Oman, Qatar, and Rest of Middle East and Africa.

Parcourir les pages associées

Banner